SCHEMBL21756757

SCHEMBL21756757

Cc1ccc(N)c(OCC(F)(F)F)n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.42
MAPT P10636 2/20 0.42
MEN1 O00255 2/20 0.42
HSP90AA1 P07900 2/20 0.42
HSP90AB1 P08238 2/20 0.42
KMT2A Q03164 2/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
KDM4E B2RXH2 1/20 0.42
USP2 O75604 1/20 0.42
THRB P10828 1/20 0.42
G6PD P11413 1/20 0.42
ALOX15 P16050 1/20 0.42
CASP1 P29466 1/20 0.42
HSD17B10 Q99714 1/20 0.42
SCN9A Q15858 2/20 0.37
CNR2 P34972 1/20 0.36
MBOAT4 Q96T53 3/20 0.36
ADORA2A P29274 1/20 0.36
AMD1 P17707 1/20 0.36
NUDT1 P36639 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23977890 0.82 CNR2 (0.50) ALDH1A1MAPTMEN1HSP90AA1HSP90AB1
SCHEMBL17490419 0.79 MAPT (0.42) ALDH1A1MAPTMEN1HSP90AA1HSP90AB1
SCHEMBL29392742 0.79 L3MBTL1 (0.42) ALDH1A1MAPTMEN1HSP90AA1HSP90AB1
SCHEMBL24251660 0.79 L3MBTL1 (0.42) ALDH1A1MAPTMEN1HSP90AA1HSP90AB1
SCHEMBL29982955 0.78 HSD17B10 (0.41) ALDH1A1MAPTMEN1KMT2AL3MBTL1
SCHEMBL23458719 0.78 HSD17B10 (0.41) ALDH1A1MAPTMEN1KMT2AL3MBTL1
SCHEMBL25009964 0.77 MBOAT4 (0.36) ALDH1A1MAPTKMT2ACASP1HSD17B10
SCHEMBL25510504 0.77 CYP2C19 (0.36) MEN1KMT2AL3MBTL1CNR2HCRTR1
SCHEMBL1704969 0.77 HSP90AA1 (0.47) ALDH1A1MAPTMEN1HSP90AA1HSP90AB1
SCHEMBL15537771 0.76 ALDH1A1 (0.46) ALDH1A1MAPTMEN1HSP90AA1HSP90AB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250034110-A1 LPAR1 ANTAGONISTS AND USES THEREOF Pipeline Therapeutics, Inc. 2025-01-30 US disclosed
EP-4380560-A1 LPAR1 ANTAGONISTS AND USES THEREOF Contineum Therapeutics, Inc. (US) 2024-06-12 EP disclosed
CN-118043041-A LPAR1 antagonists and uses thereof 康蒂内乌姆医疗公司 2024-05-14 CN disclosed
WO-2023014908-A1 LPAR1 ANTAGONISTS AND USES THEREOF Pipeline Therapeutics, Inc. (US) 2023-02-09 WO disclosed
WO-2023014908-A1 LPAR1 ANTAGONISTS AND USES THEREOF Pipeline Therapeutics, Inc. (US) 2023-02-09 WO disclosed
WO-2020038433-A1 EGFR KINASE INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF 上海艾力斯医药科技有限公司 2020-02-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250034110-A1 LPAR1 ANTAGONISTS AND USES THEREOF LPAR1, LPAR2, LPAR3 ALDH1A1 1523/4885MAPT 4647/4885MEN1 2811/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.